While statins are a cornerstone in cardiovascular care, side effects such as statin-associated myopathy remain a concern – especially among the aging population, who often require polypharmacy. But what happens when statin-related transporters are inhibited by a co-medication? Read more in our latest blog: https://hubs.ly/Q03n4TYv0 At Cyprotex, we use our transporter science expertise to assess how your investigational drug may affect statin exposure and therefore DDI risk. Get in touch to discuss your project at enquiries@cyprotex.com #theadmetoxspecialists #cyprotex #transporters
